Results 201 to 210 of about 1,625,980 (311)

Spatial transcriptomics reveals a molecular tumor budding signature in head and neck cancer. [PDF]

Genome Med
Ourailidis I, Ball M, Vogel V, He M, Wang H, Kim SB, Böning S, Wollenberg B, Wolff KD, Steiger K, Mogler C, Duensing A, Duensing S, Schirmacher P, Stenzinger A, Gires O, Kazdal D, Kirchner M, Stögbauer F, Boxberg M, Budczies J.   +20 more
europepmc   +1 more source

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

FEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani, Eiman Y. Ibrahim, Rozalyn L. Rodwin, Leah M. Ferrucci, Kim Blenman, Maryam Lustberg, Barbara E. Ehrlich   +6 more
wiley   +1 more source

Molecular and Cellular Mechanisms of Static and Repetitive Magnetic Stimulation in Cancer Therapy: A Scoping Review. [PDF]

Biomedicines
Stein D, Stieven A, Paludo RH, Fiuza KJ, Fraga LR, Fregni F, Caumo W, Jaeger MDC, Torres ILS.   +8 more
europepmc   +1 more source

Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer

FEBS Open Bio, EarlyView.
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo, Keisuke Okuno, Shuichi Watanabe, Sakiko Oba, Hiroyasu Kagawa, Masanori Tokunaga, Daisuke Ban, Yusuke Kinugasa   +7 more
wiley   +1 more source

The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application. [PDF]

Immunotargets Ther
Lamghari H, Karkouri M.
europepmc   +1 more source

Identifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1

FEBS Open Bio, EarlyView.
The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky   +7 more
wiley   +1 more source

Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative. [PDF]

Int J Mol Sci
Saha N, Lee SG, de Stanchina E, Mendoza RP, Veach DR, Nikolov DB.   +5 more
europepmc   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer. [PDF]

JCO Precis Oncol
Terashima R, Fan J, Gunturkun F, Nieda G, Fan X, Rodriguez EM, Tan AX, Thottunkal S, Shaw M, Su CC, Khan A, Ding VY, Luo I, Satoyoshi M, Bhat A, Gu B, Henry SM, Ellis-Caleo TJ, Odden M, Kurian AW, Neal JW, Wakelee HA, Wu JT, Han SS.   +23 more
europepmc   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source